tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Jonathan Demchick, 5 are a BUY (31.25%), 8 are a HOLD (50%), 3 are a SELL (18.75%).
Analyst Jonathan Demchick, carries an average stock price target met ratio of 85.71% that have a potential upside of 8.87% achieved within 279 days. Previously, Jonathan Demchick worked at MORGAN STANLEY.
Jonathan Demchick’s has documented 31 price targets and ratings displayed on 5 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on NUVA, NuVasive at 04-Aug-2023.
Analyst best performing recommendations are on GMED (GLOBUS MEDICAL).
The best stock recommendation documented was for NUVA (NUVASIVE) at 5/31/2023. The price target of $40 was fulfilled within 12 days with a profit of $1.84 (4.82%) receiving and performance score of 4.02.
Average potential price target upside
Analyst name
Rating
Rating initiation date
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
Since 20-May-2024
$115
$22.48 (24.30%)
$80
16 days ago
(08-Jan-2026)
19/21 (90.48%)
$20.38 (21.54%)
368
Buy
Since 18-Nov-2025
$105
$12.48 (13.49%)
$93
2 months 6 days ago
(18-Nov-2025)
28/30 (93.33%)
$21.58 (25.87%)
322
Buy
Since 17-Jun-2013
$114
$21.48 (23.22%)
$103
2 months 14 days ago
(10-Nov-2025)
21/23 (91.3%)
$27.64 (32.01%)
359
Buy
Since 07-Aug-2024
$79
$-13.52 (-14.61%)
$93
2 months 17 days ago
(07-Nov-2025)
12/13 (92.31%)
$17.29 (28.02%)
240
Hold
Since 08-Jan-2025
$91
$-1.52 (-1.64%)
$97
2 months 17 days ago
(07-Nov-2025)
9/10 (90%)
$29.29 (47.46%)
426
What Year was the first public recommendation made by Jonathan Demchick?
